Clinical Trial Update: Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 extension study of ranibizumab (rhuFab V2) for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED